4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: Design, synthesis and structure-activity relationships

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 10, 2009, Pages 2829-2834

  Fish, Paul V ^a   Andrews, Mark D ^a   Jonathan Fray, M ^a   Stobie, Alan ^a   Wakenhut, Florian ^a   Whitlock, Gavin A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

3 Piperidine; 3 Pyrrolidine; 4 Piperidine; Dual SNRI; Monoamine reuptake inhibitor; Selective NRI; Selective SRI; Triple SNDRI

Indexed keywords

AMINE; DULOXETINE; MILNACIPRAN; NORADRENALIN UPTAKE INHIBITOR; PIPERIDINE DERIVATIVE; PYRIDINE; PYRROLIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; NONHUMAN; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DRUG DESIGN; NOREPINEPHRINE; PIPERIDINES; PYRROLIDINES; RATS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65349171634     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.03.090     Document Type: Article

References (28)

1. Montgomery S. Int. J. Psych. Clin. Pract. 10 (2006) 5
2. Baldwin D.S. Int. J. Psych. Clin. Pract. 10 (2006) 12
3. Ueceyler N., Haeuser W., and Sommer C. Arthritis Rheumatism 58 (2008) 1279
4. Wernicke J.F., Iyengar S., and Ferrer-Garcia M.D. Curr. Drug Therapy 2 (2007) 161
5. Mariappan P., Alhasso A., Ballantyne Z., Grant A., and N'Dow J. Eur. Urology 51 (2007) 67
6. For a recent review, see: Whitlock, G. A.; Andrews, M. D.; Brown, A. D.; Fish, P. V.; Stobie, A.; Wakenhut, F. Top. Med. Chem. Published on-line 11th December, 2008. doi:10.1007/7355_2008_028.
7. Cheng X.-M. Ann. Rep. Med. Chem. 30 (1995) 295
8. Hedge S., and Schmidt M. Ann. Rep. Med. Chem. 40 (2005) 443
9. Galaatsis P. Ann. Rep. Med. Chem. 33 (1998) 338
10. For recent reviews of new SNRI chemical entities, see:. Walter M.W. Drug Dev. Res. 65 (2005) 97
11. Huang Y., and Williams W.A. Expert Opin. Ther. Patents 17 (2007) 889
12. Fish P.V., Barta N.S., Gray D.L.F., Ryckmans T., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 18 (2008) 4355 and references cited therein
13. Baldessarini, R. J. In Goodmans and Gilman's The Pharmacological Basis of Therapeutics, 11th ed.; Brunton, L. L.; Lazo, J. S.; Parker, K. L., Eds.; McGraw-Hill: New York, 2005; Chapter 17, p 429.
14. Orjales A., Mosquera R., Toledo A., Pumar M.C., Gracia N., Cortizo L., Labeaga L., and Innerarity A. J. Med. Chem. 46 (2003) 5512
15. For an analysis of the influence of drug lipophilicity on off-target pharmacology and in vivo toxicological outcomes, see:. Leeson P.D., and Springthorpe B. Nat. Rev. Drug Dis. 6 (2007) 881
16. Hughes J.D., Blagg J., Price D.A., Bailey S., De Crescenzo G.A., Dalvie D., Devraj R.V., Doubovetzky M., Ellsworth E., Fobian Y.M., Gibbs M.E., Gilles R.W., Grant D., Greene N., Huang E., Kreiger-Burke T., Lee L., Loesel J., Nahas K., Wager T., Whiteley L., and Zhang Y. Bioorg. Med. Chem. Lett. 18 (2008) 4872
17. Hitchcock S.A., and Pennington L.D. J. Med. Chem. 49 (2006) 1
18. Culbertson T.P., Domagala J.M., Nichols J.B., Priebe S., and Skeean R.W. J. Med. Chem. 30 (1987) 1715
19. Zheng X., Day C., and Gollamudi R. Chirality 7 (1995) 90
20. Fray M.J., Bish G., Brown A.D., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4345
21. For examples of SNRIs, see:. Boot J., Cases M., Clark B.P., Findlay J., Gallagher L.H., Man T., Montalbetti C., Rathmell R.E., Rudyk H., Walter M.W., Whatton M., and Wood V. Bioorg. Med. Chem. Lett. 15 (2005) 699
22. Fish P.V., Deur C., Gan X., Greene K., Hoople D., Mackenny M., Para K.S., Reeves K., Ryckmans T., Stiff C., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 18 (2008) 2562
23. a: measured ionisation constant; HBD: H-bond donor count (NH+OH); HBA: H-bond acceptor count (N+O); TPSA: topological polar surface area.
24. 2.
25. 3-Piperidines have been reported as NRIs, see: Caprathe, B. W.; Gogliotti, R. D.; Jennings, R. A.; Simons, L. J. WO Patent Application 023258, 2008.
26. For a comprehensive review, see:. Shen D.D., Artru A.A., and Adkison K.K. Adv. Drug Delivery Rev. 56 (2004) 1825
27. For published values of rat CSF to free plasma levels for fluoxetine and atomoxetine, see:. Liu X., Smith B.J., Chen C., Callegari E., Becker S.L., Chen X., Cianfrogna J., Doran A.C., Doran S.D., Gibbs J.P., Hosea N., Liu J., Nelson F.R., Szewc M.A., and Deusen J.V. Drug Metab. Dispos. 34 (2006) 1443
28. Kielbasa W., Kalvass J.C., and Stratford R. Drug Metab. Dispos. 37 (2009) 137